ACM
IOVA icon

Armbruster Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Armbruster Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,200
Closed -$16K – 267
2017
Q2 		$16K Hold
2,200
– – 0.01% 187
2017
Q1 		$16K Hold
2,200
– – 0.01% 189
2016
Q4 		$15K Hold
2,200
– – 0.01% 193
2016
Q3 		$18K Buy
+2,200
New +$18.6K 0.01% 183

Other funds holding IOVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Armbruster Capital Management's IOVA Position: Q3 2017 in Review

Armbruster Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2017, closing a stake of 2,200 shares — an estimated $16K sold.

Armbruster Capital Management first reported a position in IOVA in Q3 2016 and held it in 4 quarters. The position peaked at $18K in Q3 2016. 85 funds tracked by Wall St. Rank hold IOVA as of Q3 2017.

  • Armbruster Capital Management reported no remaining Iovance Biotherapeutics position as of Q3 2017 after selling out during the quarter.
  • Armbruster Capital Management sold 2,200 Iovance Biotherapeutics shares in Q3 2017, an estimated $16K.
  • Armbruster Capital Management first reported a position in Iovance Biotherapeutics in Q3 2016 and held it in 4 quarters.
  • Armbruster Capital Management's Iovance Biotherapeutics position peaked at $18K in Q3 2016.
  • 85 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2017.

Based on Armbruster Capital Management's 13F filing for Q3 2017, filed 8 Nov 2017.